ModerateVitamin K antagonist anticoagulants×Antituberculous antibiotic
Updated · Methodology
Mechanism
Liver enzymes, mainly CYP2C9, metabolise acenocoumarol, and inducers of CYP2C9, CYP2C19 and CYP3A4 can reduce its anticoagulant effect (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Rifampicin is a potent inducer of drug-metabolising enzymes, including CYP1A2, CYP2C9, CYP2C19 and CYP3A4, and can speed up the metabolism of other drugs and reduce their effect (rifampicin SmPC, AEMPS). The acenocoumarol SmPC names rifampicin among the drugs that can reduce the anticoagulant effect of acenocoumarol (acenocoumarol SmPC, AEMPS). The documents do not say how much acenocoumarol levels fall. Data exist only for warfarin: rifampicin 600 mg daily reduced the area under the concentration–time curve (AUC) of S-warfarin by 74% (rifampicin SmPC, AEMPS). Rifampicin itself can cause vitamin K-dependent coagulation disorders and severe bleeding (rifampicin SmPC, AEMPS).
Symptoms
The anticoagulant effect of acenocoumarol can weaken: the international normalised ratio (INR) falls below the target range, and protection against clots, the reason for acenocoumarol treatment, weakens (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At the same time, rifampicin itself can cause vitamin K-dependent coagulation disorders and severe bleeding (rifampicin SmPC, AEMPS). After rifampicin is stopped, the effect of acenocoumarol can increase again, especially if its dose was raised. With excess acenocoumarol, the most frequent signs are bleeding into the skin and blood in the urine. Other signs include bruising, gastrointestinal bleeding, vomiting blood, uterine bleeding, nosebleeds, bleeding gums and bleeding into joints (acenocoumarol SmPC, AEMPS).
Management
The combination is not contraindicated but needs close coagulation monitoring. The acenocoumarol summary of product characteristics (SmPC) lists rifampicin among drugs that can reduce its effect. It asks for close and frequent coagulation checks, for example twice a week, both when such a drug is added and when it is stopped (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the Spanish rifampicin SmPCs, anticoagulants, including coumarins, are among the drugs affected by rifampicin, and their dose may need adjustment when rifampicin is started or stopped (rifampicin SmPCs, AEMPS). The US rifampicin label says to measure the prothrombin time daily or as often as needed to establish and maintain the required dose of an oral anticoagulant (rifampicin prescribing information, US Food and Drug Administration, FDA). In people at risk of vitamin K deficiency, including those on long-term anticoagulants, monitor the prothrombin time and other coagulation tests during rifampicin treatment. If the tests are abnormal or bleeding occurs, consider stopping rifampicin (rifampicin prescribing information, FDA). The Spanish SmPC advises watching for coagulopathy in people at particular risk of bleeding (rifampicin SmPC, AEMPS). A change in the acenocoumarol dose does not show in the prothrombin time for at least 36 hours. In patients outside the target range, the effect of a dose change is usually assessed after 7–8 days. Base dose adjustments on the total weekly dose (acenocoumarol SmPC, AEMPS). With an international normalised ratio (INR) of 4.5–10 and no significant bleeding, interrupt acenocoumarol. With an INR above 10, also give 1–5 mg of vitamin K1 by mouth. In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Rifampin capsule (Ani Pharmaceuticals, Inc.) – Prescribing Information (2022)– DailyMed setid b389b1a3-672f-47e3-916c-4a9c044b211b
- AEMPS: Ficha técnica de Rifaldin 300 mg cápsulas (rifampicina) (2026)– AEMPS, CIMA, nº registro 46029, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Rifampicina (nº registro 49034), sección 4.5 (2026)– AEMPS, CIMA, nº registro 49034, revisión 08/2026, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.2 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.2 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.2
- AEMPS: Ficha técnica: Rifampicina, Rifaldin 300 mg (nº registro 46029), sección 4.4 (2026)– AEMPS, CIMA, nº registro 46029 (Rifaldin 300 mg cápsulas, Sanofi Aventis), revisión 04/2026 (texto revisado 03/2026), secciones 4.4 y 4.8